Corrigendum: Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein

• Mariana Nunes,
• Mariana Nunes,
• Patrícia M. A. Silva,
• Patrícia M. A. Silva,
• Ricardo Coelho,
• Carla Pinto,
• Carla Pinto,
• Albina Resende,
• Albina Resende,
• Hassan Bousbaa,
• Gabriela M. Almeida,
• Gabriela M. Almeida,
• Sara Ricardo,
• Sara Ricardo,
• Sara Ricardo

Affiliations

Mariana Nunes

Differentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto/Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal

Mariana Nunes

Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal

Patrícia M. A. Silva

CESPU, Institute of Research and Advanced Training in Health Sciences and Technologies (IINFACTS), Gandra, Portugal

Patrícia M. A. Silva

TOXRUN, Toxicology Research Unit, University Institute of Health Sciences, Polytechnic and University Cooperative (CESPU), Gandra, Portugal

Ricardo Coelho

Ovarian Cancer Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland

Carla Pinto

CESPU, Institute of Research and Advanced Training in Health Sciences and Technologies (IINFACTS), Gandra, Portugal

Carla Pinto

Interdisciplinary Centre of Marine and Environmental Research (CIIMAR), University of Porto, Porto, Portugal

Albina Resende

CESPU, Institute of Research and Advanced Training in Health Sciences and Technologies (IINFACTS), Gandra, Portugal

Albina Resende

Interdisciplinary Centre of Marine and Environmental Research (CIIMAR), University of Porto, Porto, Portugal

Hassan Bousbaa

CESPU, Institute of Research and Advanced Training in Health Sciences and Technologies (IINFACTS), Gandra, Portugal

Gabriela M. Almeida

Expression Regulation in Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto/Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal

Gabriela M. Almeida

Faculty of Medicine from University of Porto (FMUP), Porto, Portugal

Sara Ricardo

Differentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto/Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal

Sara Ricardo

TOXRUN, Toxicology Research Unit, University Institute of Health Sciences, Polytechnic and University Cooperative (CESPU), Gandra, Portugal

Sara Ricardo

Faculty of Medicine from University of Porto (FMUP), Porto, Portugal